文献速递神经免疫

自体造血干细胞移植治疗多发性硬化的长期结局

Long-term Outcomes After Autologous Hematopoietic Stem Cell Transplantation for Multiple Sclerosis.
PubMed 文献 · JAMA Neurol · 2017-01-01

这项多中心回顾性队列研究纳入1995至2006年间接受自体造血干细胞移植(AHSCT)的281例多发性硬化(MS)患者,中位随访6.6年。结果显示5年无进展生存概率为46%,总生存率为93%,移植相关死亡率为2.8%。年轻、复发型MS、既往免疫治疗较少和基线EDSS较低与更好结局相关。

要点

  • AHSCT后近半数MS患者5年内无神经功能进展。
  • 移植相关死亡率为2.8%,5年总生存率达93%。
  • 年轻、复发型、既往治疗少和基线EDSS低者预后更佳。

核心结论

  • 在这项接受AHSCT治疗的MS观察性研究中,近一半患者移植后5年内保持无神经功能进展。
  • 年轻、复发型MS、既往免疫治疗较少和基线EDSS评分较低是与更好结局相关的因素。
  • 结果支持进一步开展AHSCT治疗MS的随机临床试验。

研究设计与样本

  • 多中心、观察性、回顾性队列研究,数据来自13个国家25个中心。
  • 纳入1995年1月至2006年12月期间因MS接受AHSCT且有预设最低数据集的281例可评估患者。
  • 中位随访6.6年(范围0.2-16年),末次患者访视于2012年7月1日。

主要发现

  • 移植后100天内报告8例死亡(2.8%;95%CI 1.0%-4.9%),归为移植相关死亡。
  • 5年无进展生存概率(基于EDSS)为46%(95%CI 42%-54%),5年总生存率为93%(95%CI 89%-96%)。
  • 移植后神经进展的相关因素包括年龄较大(HR 1.03;95%CI 1.00-1.05)、进展型vs复发型MS(HR 2.33;95%CI 1.27-4.28)和既往超过2种疾病修正治疗(HR 1.65;95%CI 1.10-2.47)。
  • 基线EDSS评分较高与更差的总生存相关(HR 2.03;95%CI 1.40-2.95)。

临床怎么用

  • 对于年轻、复发型且既往免疫治疗较少的MS患者,AHSCT可能带来更优的长期无进展生存。
  • 基线EDSS评分较高的患者总生存较差,选择AHSCT时需谨慎评估。
  • 移植相关死亡风险需在决策中权衡,尤其对于进展型MS患者。

局限性

  • 为观察性、回顾性研究,可能存在选择偏倚和混杂因素。
  • 随访时间范围较宽(0.2-16年),部分患者随访时间较短。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Autologous hematopoietic stem cell transplantation (AHSCT) may be effective in aggressive forms of multiple sclerosis (MS) that fail to respond to standard therapies. OBJECTIVE: To evaluate the long-term outcomes in patients who underwent AHSCT for the treatment of MS in a large multicenter cohort. DESIGN, SETTING, AND PARTICIPANTS: Data were obtained in a multicenter, observational, retrospective cohort study. Eligibility criteria were receipt of AHSCT for the treatment of MS between January 1995 and December 2006 and the availability of a prespecified minimum data set comprising the disease subtype at baseline; the Expanded Disability Status Scale (EDSS) score at baseline; information on the administered conditioning regimen and graft manipulation; and at least 1 follow-up visit or report after transplant. The last patient visit was on July 1, 2012. To avoid bias, all eligible patients were included in the analysis regardless of their duration of follow-up. Data analysis was conducted from September 1, 2014 to April 27, 2015. EXPOSURES: Demographic, disease-related, and treatment-related exposures were considered variables of interest, including age, disease subtype, baseline EDSS score, number of previous disease-modifying treatments, and intensity of the conditioning regimen. MAIN OUTCOMES AND MEASURES: The primary outcomes were MS progression-free survival and overall survival. The probabilities of progression-free survival and overall survival were calculated using Kaplan-Meier survival curves and multivariable Cox proportional hazards regression analysis models. RESULTS: Valid data were obtained from 25 centers in 13 countries for 281 evaluable patients, with median follow-up of 6.6 years (range, 0.2-16 years). Seventy-eight percent (218 of 281) of patients had progressive forms of MS. The median EDSS score before mobilization of peripheral blood stem cells was 6.5 (range, 1.5-9). Eight deaths (2.8%; 95% CI, 1.0%-4.9%) were reported within 100 days of transplant and were considered transplant-related mortality. The 5-year probability of progression-free survival as assessed by the EDSS score was 46% (95% CI, 42%-54%), and overall survival was 93% (95% CI, 89%-96%) at 5 years. Factors associated with neurological progression after transplant were older age (hazard ratio [HR], 1.03; 95% CI, 1.00-1.05), progressive vs relapsing form of MS (HR, 2.33; 95% CI, 1.27-4.28), and more than 2 previous disease-modifying therapies (HR, 1.65; 95% CI, 1.10-2.47). Higher baseline EDSS score was associated with worse overall survival (HR, 2.03; 95% CI, 1.40-2.95). CONCLUSIONS AND RELEVANCE: In this observational study of patients with MS treated with AHSCT, almost half of them remained free from neurological progression for 5 years after transplant. Younger age, relapsing form of MS, fewer prior immunotherapies, and lower baseline EDSS score were factors associated with better outcomes. The results support the rationale for further randomized clinical trials of AHSCT for the treatment of MS.

来源:JAMA Neurol,查看原文。版权归原作者所有。

引用

  1. Muraro PA, Pasquini M, Atkins HL, et al. Long-term Outcomes After Autologous Hematopoietic Stem Cell Transplantation for Multiple Sclerosis. JAMA Neurol. 2017. PMID: 28241268. doi:10.1001/jamaneurol.2016.5867

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。